(PharmaNewsWire.Com, December 05, 2018 ) According to the new market research report “Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) - Global Forecast to 2023", published by MarketsandMarkets™, The global autoinjectors market is projected to reach USD 85.31 billion by 2023 from an estimated USD 28.91 billion in 2018, at a CAGR of 24.2% during the forecast period (2018-2023). The key factors driving the growth of this market include the growing prevalence of targeted therapies such as rheumatoid arthritis and multiple sclerosis, rising incidence of anaphylaxis, and increasing number of regulatory approvals.
Don’t miss out on business opportunities in “Autoinjectors Market”. Speak to our analyst and gain crucial industry insights that will help your business grow: http://bit.ly/2Q7wlrE Autoinjectors offer several advantages, such as reduces the chances of needlestick injuries, reduce needle phobia anxiety, maintain consistency regarding dose accuracy, and aid in better efficacy, which, in turn, help in the growth of the market. The autoinjectors market is expanding with the technological advancement and new design development. These autoinjectors are being used in many therapies such as rheumatoid arthritis, multiple sclerosis, diabetes, anaphylaxis, and other therapies. Use of autoinjectors in the treatment of rheumatoid arthritis drives the global autoinjectors market Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory autoimmune disease that affects connective tissues. It causes joints to swell and can result in pain, stiffness, and progressive loss of function. According to the CDC, an estimated 43.7 million adults (22.7% of the total population) in the US annually are affected by some form of arthritis, RA, gout, lupus, or fibromyalgia. Thus, the demand for autoinjectors for this therapy segment is fueled by the increasing incidence of RA across the globe. Among the various treatment options available for RA in the market, autoinjectors are the most advanced and convenient mode of tretment currently avialble in the market.
Browse and in-depth TOC on “Autoinjectors Market” 66 - Tables
The autoinjectors market comprises a network of players involved in the research and product development; component manufacturing; distribution and sale; and post-sales services. Key players considered in the analysis of the autoinjectors market are Abbvie (US), Amgen (US), Teva (Israel), Biogen (US), Eli Lilly (US), and Mylan (US). The other prominent players are Merck (US), SHL Group (Taiwan), Ypsomed (Switzerland), AstraZeneca (UK), Becton Dickinson and Company (US), Owen Mumford (UK), Novartis (Switzerland), J&J (US), and Haselmeier (Switzerland).
Major Market Developments In April, 2018, Abbvie and Samsung Bioepis signed a licensing agreement to launch Humira biosimilar in Europe. In August, 2017, Amgen and Humana entered in to collaborative agreement for the development and research of medicines for multiple serious conditions including cardiovascular disease, osteoporosis, neurologic disorders, inflammatory diseases and cancer. In May, 2018, Received EU approval for Repatha autoinjector. Similarly, the company has launched Enbrel auto-touch auto-injector in November, 2017. Request for Free Sample Report @ http://bit.ly/2DXG2BC Browse Adjacent Markets @ Medical Devices Market Research Reports & Consulting About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
